QURE
uniQure NV
NASDAQ · Healthcare · Biotechnology · NL
$22.20
+1.93%Year over year
Reported trailing growth
- Revenue
- +30.2%
- EBITDA
- -51.4%
- EBIT
- -20.1%
- EPS
- -3.1%
- Free cash flow
- +11.8%
- Operating cash flow
- +7.3%
Forward estimates
Based on analyst estimates
- Revenue
- +196.6%
- EBITDA
- -5.0%
- EPS
- +1.1%
Three-year CAGR
- Revenue
- -46.7%
- EBITDA
- +27.5%
- EBIT
- -1.9%
- Net income
- +16.9%
- EPS
- +29.7%
- Free cash flow
- +4.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026